Insmed (INSM) PT Raised to $40 at BofA Securities
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $118.34 -2.05%
Rating Summary:
32 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 6 | New: 39
Rating Summary:
32 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 6 | New: 39
Join SI Premium – FREE
BofA Securities analyst Jason Zemansky raised the price target on Insmed (NASDAQ: INSM) to $40.00 (from $37.00) while maintaining a Buy rating.
You May Also Be Interested In
- Constellation Brands (STZ) PT Lowered to $145 at UBS on Softer Consumer Backdrop
- Pepsico (PEP) PT Lowered to $161 at BNP Paribas Exane, 'Expect Renewed Calls for Greater Urgency in NA'
- FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
